CEDAR KNOLLS, N.J.,
Jan. 15, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and the
owner of Fortetropin®, a proprietary bioactive
composition derived from fertilized egg yolk that helps build lean
muscle, announced today positive top-line
results from a randomized, double-blind,
placebo-controlled study by Kansas State
University evaluating the impact of Fortetropin on
attenuating muscle atrophy following a common surgical procedure
known as tibial-plateau leveling osteotomy ("TPLO") in
100 dogs.
In the weeks that follow TPLO surgery, immobilization of the
dog's limb is required and the operated limb frequently shows
significant muscle loss due to muscle disuse atrophy. The
objective of the study, which was sponsored by the Company, was to
determine whether Fortetropin could reduce this muscle atrophy.
Key findings of the study:
- Fortetropin prevented the loss of muscle mass in these dogs as
measured by the thigh circumference in their affected and
unaffected limbs.
- Fortetropin-supplemented dogs had a more significant
improvement in percentage of weight supported by the affected limb
as determined by force plate stance analysis (more rapid return to
normal stance force distribution) than the placebo group.
- Fortetropin prevented a rise in serum myostatin levels.
Myostatin is a protein that prevents muscle growth.
Kenneth R. Harkin, DVM, DACVIM
(SAIM), Professor and Section Head, College of Veterinary
Medicine, Kansas State University, and principal investigator
of the study commented, "This study demonstrates the benefits of
Fortetropin in dogs with prolonged post-operative recovery
periods. Restoration or maintenance of muscle mass through
the reduction of serum myostatin levels with Fortetropin offers
veterinarians a novel approach to in-home rehabilitation of injured
dogs, including potentially improving or restoring mobility in
geriatric dogs."
Joseph Mannello, CEO of MYOS,
commented, "We believe the results of this study will be
transformative for MYOS. First, we expect the study results will
enable us to expand our veterinary business with a product that is
truly disruptive and can change the way pet owners and
veterinarians address canine muscle health. Second, the study
results reinforce our plans to pursue clinical trials for human
rehabilitation and recovery. These areas of tremendous market
potential will be discussed further during our conference call
later, today."
Professor Harkin will present an oral summary of study results
on January 20, 2019 at
the North American Veterinary Community (NAVC) / VMX Conference
(https://navc.com/vmx/) in Orlando, Florida. The
presentation will be entitled, "The Impact of
Fortetropin® Supplementation
on Dogs Recovering from Tibial-Plateau Leveling Osteotomy (TPLO)
Surgery" and will be presented in the
Discovery Theater at the VMX Conference at
3:15 pm.
Conference Call Details:
Call
Date/Time:
|
Tuesday, January 15,
2019 at 11:00 am ET
|
|
|
Call
Title:
|
MYOS RENS Technology
Business Update Conference Call
|
|
|
Dial
In:
|
877-407-4019 from the
U.S.; international callers may telephone
|
|
201-689-8337,
approximately 10 minutes before the call.
|
A digital replay will be available by telephone approximately
two hours after the completion of the call until April 15, 2019 and may be accessed by dialing
877-660-6853 from the U.S. or 201-612-7415 for international
callers, using the Conference ID# 13686568.
This call will be simultaneously webcast. The webcast will be
available on the MYOS website, www.myosrens.com, in the "Investor
Relations" section. The webcast will be archived and available at
the same web address for two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in this release that are not historical facts
are forward-looking statements. Actual results may differ
materially from those projected or implied in any forward-looking
statements. Such statements involve risks and uncertainties,
including but not limited to those relating to product and customer
demand, market acceptance of our products, the ability to create
new products through research and development, the successful
results of strategic initiatives, the successful launch of our
products, including Qurr®, Yolked®,
MYOS Enteral Nutrition Formula™ and MYOS Canine
Muscle Formula™ products, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-study-results-demonstrating-fortetropin-the-active-ingredient-in-myos-canine-muscle-formula-prevents-muscle-loss-in-canines-after-surgery-and-enhances-recovery-300777991.html
SOURCE MYOS RENS Technology